Drug Profile
SP 20102
Alternative Names: SP20102Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Sarfez Pharmaceuticals
- Class Antifibrotics; Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for phase-I development in Fibrosis in USA
- 05 Dec 2015 Phase-I clinical trials in Fibrosis in USA (unspecified route) prior to December 2015